New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic

New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic

Marco Caminati,1,2 Diego Bagnasco,3 Rachele Vaia,2 Gianenrico Senna11Asthma Center and Allergy Unit, Verona University Hospital, Verona, Italy; 2Department of Medicine, School of Specialization in Allergy and Clinical Immunology, University of Verona, Verona, Italy; 3Allergy & Respiratory Di...

Full description

Bibliographic Details
Main Authors:	Caminati M, Bagnasco D, Vaia R, Senna G
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-05-01
Series:	Biologics: Targets & Therapy
Subjects:	Benralizumab efficacy benralizumab safety benralizumab mechanism of action anti IL-5 mAbs severe asthma eosinophilic asthma
Online Access:	https://www.dovepress.com/new-horizons-for-the-treatment-of-severe-eosinophilic-asthma-benralizu-peer-reviewed-article-BTT

Similar Items

Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
by: Alistair Cook, et al.
Published: (2021-05-01)

Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis
by: Cristiano Caruso, et al.
Published: (2022-09-01)

Reliability, Satisfaction and Effectiveness of Benralizumab Home Self-Administration in Patients with Severe Eosinophilic Asthma in Real-World Practice: The Auto-Benra Study
by: García-Moguel I, et al.
Published: (2022-05-01)

Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
by: Carlos Martínez-Rivera, et al.
Published: (2021-01-01)

Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study
by: Cameli P, et al.
Published: (2024-03-01)

Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy
by: Corrado Pelaia, et al.
Published: (2021-12-01)

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
by: Pelaia C, et al.
Published: (2018-03-01)

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
by: Alessandra Vultaggio, et al.
Published: (2023-05-01)

Case Report: Severe Eosinophilic Asthma Associated With ANCA-Negative EGPA in a Young Adult Successfully Treated With Benralizumab
by: Luisa Ricciardi, et al.
Published: (2022-04-01)

Elaborate biologic approval process delays care of patients with moderate-to-severe asthma
by: Esha Sehanobish, PhD, et al.
Published: (2023-05-01)

Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma
by: Drick N, et al.
Published: (2020-11-01)

Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis
by: Hiroaki Tsurumaki, et al.
Published: (2019-07-01)

Effectiveness of Benralizumab in Improving the Quality of Life of Severe Eosinophilic Asthmatic Patients: Our Real-Life Experience
by: Giulia Scioscia, et al.
Published: (2021-02-01)

Successful discontinuation of corticosteroids through remission induction therapy with benralizumab for chronic eosinophilic pneumonia
by: Yoshiro Kai, et al.
Published: (2024-01-01)

Rapid and remarkable effectiveness of benralizumab for treating severe bronchial asthma with intractable eosinophilic rhinosinusitis and eosinophilic otitis media: A case report
by: Hideyasu Shimizu, et al.
Published: (2021-01-01)

Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)
by: Eva Martínez-Moragón, et al.
Published: (2021-12-01)

Benralizumab: Effectiveness in Patients with Uncontrolled Severe Eosinophilic Asthma at 6 and 12 Months at a Third-Level Care Hospital. Capacity for ICS-LABA Therapy Reduction
by: González-Tuyub YH, et al.
Published: (2024-11-01)

Patient-Reported Outcomes with Benralizumab in Patients with Severe Eosinophilic Asthma and Severe Chronic Rhinosinusitis with Nasal Polyps
by: Rory Chan, et al.
Published: (2023-03-01)

A case of paradoxical eosinophilic fasciitis in a patient on benralizumab
by: Michael J. Woodbury, BS, et al.
Published: (2023-10-01)

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
by: Maria D'Amato, et al.
Published: (2022-05-01)

Safety and efficacy of monoclonal antibodies targeting IL-5 in severe eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials
by: Noor Alam, et al.
Published: (2023-09-01)

Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression
by: Pelaia C, et al.
Published: (2021-02-01)

Rapid onset of effect of benralizumab in a severe eosinophilic and allergic asthma patient with allergic bronchopulmonary aspergillosis
by: Arvindran Alaga, et al.
Published: (2023-06-01)

Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study
by: Takanori Numata, et al.
Published: (2020-08-01)

Successful Introduction of Benralizumab for Eosinophilic Ascites
by: Nabil Belfeki, et al.
Published: (2024-01-01)

Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series
by: Menzella F, et al.
Published: (2021-02-01)

Medium-term repeatability for airwave oscillometry in patients with severe asthma taking benralizumab
by: Rory Chan, MBChB, PhD, et al.
Published: (2023-08-01)

New therapy options for patients with eosinophilic type of severe bronchial asthma
by: G. L. Ignatova, et al.
Published: (2020-01-01)

Efficacy and safety of benralizumab in elderly patients with severe eosinophilic asthma
by: Kohei Somekawa, et al.
Published: (2024-12-01)

Real-life cost-effectiveness of benralizumab in patients with severe asthma
by: A. Padilla-Galo, et al.
Published: (2021-05-01)

Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings
by: M. V. Zhuravleva, et al.
Published: (2022-07-01)

Treatment of Widespread Eosinophilic Cellulitis (Wells’ Syndrome) with Benralizumab
by: Maria Blomberg, et al.
Published: (2020-11-01)

Benralizumab‐resistant mucus plugs in severe asthma complicated by eosinophilic chronic rhinosinusitis
by: Masamitsu Hamakawa, et al.
Published: (2024-08-01)

Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases
by: Sriram Sridhar, et al.
Published: (2019-01-01)

Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis
by: Osamu Matsuno, et al.
Published: (2022-01-01)

Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma
by: S. K. Zyryanov, et al.
Published: (2020-12-01)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
by: Erminia Ridolo, et al.
Published: (2020-10-01)

Benralizumab use in chronic eosinophilic pneumonia with eosinophilic bronchiolitis and chronic airway infection
by: Tomotsugu Takano, et al.
Published: (2021-08-01)

Autoimmune hepatitis with eosinophilic infiltration responsive to anti-interleukin-5 receptor treatment: a case report and literature review
by: Francesca Romana Ponziani, et al.
Published: (2023-10-01)

Severe Asthma or Chronic Obstructive Pulmonary Disease with Eosinophilic Inflammation? From Uncertainty to Remission under Anti IL-5R Therapy
by: Bianca Oprescu, et al.
Published: (2024-02-01)